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Abstract
Background: Connective tissue growth factor (CTGF) is widely thought to promote the development of fibrosis in
collaboration with transforming growth factor (TGF)-b; however, most of the evidence for its involvement comes
from correlative and culture-based studies. In this study, the importance of CTGF in tissue fibrosis was directly
examined in three murine models of fibrotic disease: a novel model of multiorgan fibrosis induced by repeated
intraperitoneal injections of CTGF and TGF-b2; the unilateral ureteral obstruction (UUO) renal fibrosis model; and an
intratracheal bleomycin instillation model of pulmonary fibrosis.
Results: Intraperitoneal coadministration of CTGF and TGF-b2 elicited a profound fibrotic response that was
inhibited by the human anti-CTGF antibody FG-3019, as indicated by the ability of FG-3019 to ameliorate the
histologic signs of fibrosis and reduce the otherwise increased hydroxyproline:proline (Hyp:Pro) ratios by 25% in
kidney (P < 0.05), 30% in liver (P < 0.01) and 63% in lung (P < 0.05). Moreover, administration of either cytokine
alone failed to elicit a fibrotic response, thus demonstrating that CTGF is both necessary and sufficient to initiate
fibrosis in the presence of TGF-b and vice versa. In keeping with this requirement for CTGF function in fibrosis, FG-
3019 also reduced the renal Hyp:Pro response up to 20% after UUO (P < 0.05). In bleomycin-injured animals, a
similar trend towards a FG-3019 treatment effect was observed (38% reduction in total lung Hyp, P = 0.056). Thus,
FG-3019 antibody treatment consistently reduced excessive collagen deposition and the pathologic severity of
fibrosis in all models.
Conclusion: Cooperative interactions between CTGF and TGF-b signaling are required to elicit overt tissue fibrosis.
This interdependence and the observed anti-fibrotic effects of FG-3019 indicate that anti-CTGF therapy may
provide therapeutic benefit in different forms of fibroproliferative disease.
Background
Fibroproliferative diseases, including chronic pulmonary,
hepatic, renal and vascular fibrosis, contribute to nearly
half of all deaths in the USA[1,2]. These disorders fre-
quently affect multiple organ systems, complicating the
elucidation of their underlying pathogenesis and hinder-
ing the development of effective treatments. Neverthe-
less, two secreted factors, transforming growth factor
(TGF-b and connective tissue growth factor (CTGF), are
widely regarded as universal mediators of fibrogenesis,
although the precise mechanisms that underlie their
concerted effects remain unclear [3-8]. Because TGF-b
is a potent inducer of CTGF, most models postulate
that CTGF acts as a downstream mediator of TGF-b
activity, whereas other studies support an interdepen-
dent rather than merely sequential relationship between
TGF-b and CTGF and their respective profibrotic activ-
ities [9-11].
CTGF is a multifunctional heparin-binding glycopro-
tein that is normally expressed at low levels but drama-
tically enriched in virtually all fibrotic conditions [8].
Cell-based studies have shown that CTGF regulates
multiple processes that contribute to fibrogenesis,
including cell proliferation, migration, adhesion, survival
and extracellular matrix production; that it does so as
both a downstream and cooperative mediator of TGF-b
signaling; and that it affects a variety of cell types that
participate in the fibrogenic process, regardless of tissue
origin, including mesenchymal stem cells, hepatic * Correspondence: tseeley@fibrogen.com
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any medium, provided the original work is properly cited.stellate cells, renal podocytes, mesangial cells, parietal
and tubular epithelial cells, pulmonary type II alveolar
cells, mesothelial cells, vascular smooth muscle cells,
endothelial cells, cardiomyocytes, pericytes and fibro-
blasts [4]. Moreover, correlative studies in diseased
human tissues indicate important links between CTGF
and TGF-b in a number of fibrotic disease states,
including diabetic nephropathy, idiopathic and non-
idiopathic pulmonary fibrosis, liver fibrosis, skin fibrosis
(including keloids and systemic sclerosis), atherosclero-
sis, congestive heart failure, pancreatitis and various
forms of malignant disease [3,8].
Data from animal models of human disease also sup-
port the importance of CTGF and its interactions with
TGF-b in fibrosis. The small interfering (si)RNA-
mediated knockdown of CTGF, for example, has been
shown to suppress fibrotic responses in three models of
liver fibrosis [5,12,13] and in a chronic allograft nephro-
pathy model [14]. Similarly, antisense-mediated knock-
down of CTGF has been shown to suppress fibrosis or
its indicators in models of type 1 and type 2 diabetic
nephropathy [15], unilateral ureteral obstruction (UUO)
and subtotal (5/6) nephrectomy-induced kidney fibrosis
[16,17], chemically induced liver fibrosis [18], hyper-
trophic scarring after dermal wound repair [19], and
capsular scarring and contracture surrounding breast
implants [20]. Notably, TGF-b induction was also
reduced after siRNA- and antisense-mediated CTGF
knockdown in five of six models in which it was exam-
ined [5,12,13,15,16,18], thus indicating that CTGF activ-
ity directly or indirectly enhances the expression of its
own inducer in a positive feedback manner. In addition,
the expression of known TGF-b targets was inhibited by
antisense CTGF knockdown in the 5/6 nephrectomy
model despite concurrent overexpression of a TGF-b
transgene, suggesting that CTGF also promotes TGF-b
activity in a fibrotic setting [17]. Thus, CTGF may influ-
ence both the level and function of TGF-b and like
CTGF, the targeted inhibition of TGF-b itself attenuates
fibrogenesis in these and other disease models. However,
the myriad crucial functions of TFG-b make it unattrac-
tive as a direct target for antifibrotic therapy [3].
In the work described here, a novel CTGF and TGF-b
synergy model was developed based on the prior observa-
tion that simultaneous or serial subcutaneous coadminis-
tration of TGF-b3 and CTGF elicited the formation of
persistent fibrotic lesions in neonatal mice, whereas
administration of either cytokine alone failed to produce
any persistent effect [21]. In this study, we extended these
findings to a model in which intraperitoneal co-injections
of TGF-b2 and recombinant human CTGF produced pro-
found peritoneal fibrosis, abdominal adhesions, and disse-
minated fibrosis in vital organs, including lung, heart,
kidney and liver. As had been shown in the earlier
subcutaneous fibrosis model, fibrosis in the intraperitoneal
administration model also required the coadministration
of both TGF-b and CTGF, thus demonstrating a robust
cooperative interaction between these two factors in the
genesis and maintenance of a fibrotic response. Further-
more, FG-3019, a fully human recombinant monoclonal
antibody against human CTGF, blocked fibrosis in this
model and in two additional clinically relevant rodent
fibrosis models, the UUO model of kidney fibrosis and the
bleomycin model of lung fibrosis, both of which also
respond to TGF-b/Smad-targeted interventions [22-24].
Thus, treatment with a CTGF-blocking antibody reduced
the severity of fibrosis in all three models, thereby indicat-
ing that anti-CTGF therapy may be clinically beneficial in
diverse fibroproliferative diseases.
Results
Production and characterization of FG-3019 monoclonal
antibody
FG-3019, a fully human recombinant DNA-derived
CTGF-reactive monoclonal IgG1/ antibody, was iso-
lated and cloned from genetically engineered mice
expressing human immunoglobulin transgenes
(Medarex, Princeton, NJ, USA) [25], which had been
immunized with recombinant human CTGF. Using
engineered CTGF fusion proteins and CTGF proteolysis
fragments, FG-3019 binding activity was mapped to the
cysteine-rich von Willebrand Factor type C (VWC)
domain of CTGF (Figure 1A). Synthetic peptides derived
from the VWC domain sequences of CTGF efficiently
displaced FG-3019 in competitive CTGF ELISAs, includ-
ing a peptide corresponding to CTGF amino acids 135-
157, suggesting that these sequences participate in the
recognition and binding of CTGF by FG-3019. This seg-
ment of the CTGF primary sequence is poorly con-
served between related CCN family proteins, including
NOV and CYR61 but well conserved within CTGF pro-
teins encoded by diverse mammalian species [26].
Indeed, FG-3019 binds CTGF from a variety of mamma-
lian species, including rodents, and radioimmunoassays
indicate that it binds human and rat CTGF with Kd
values of approximately 0.1 and 0.3 nmol/l, respectively
(data not shown). To confirm the specificity of FG-3019
towards CTGF, as opposed to the structurally related
CCN proteins CYR61 or NOV, binding of FG-3019 to
recombinant proteins was compared by immunoblot
analysis; FG-3019 was indeed avidly associated with
CTGF, but not with CYR61 or NOV (Figure 1B). This
result was also confirmed by ELISA (data not shown).
Profibrotic effects of TGFb2 and CTGF coadministration in
neonatal mice
A novel model of multiorgan fibrosis was developed,
involving the repeated intraperitoneal injection of
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Whereas the gross anatomy of control mice treated with
vehicle, TGF-b2 or CTGF alone appeared normal, ani-
mals treated with both cytokines together exhibited a
profound thickening of the abdominal wall and perito-
neal membrane (Figure 2A, B). In severe cases, a thick-
ened fibrous membrane covered the surface of almost all
the abdominal organs, and fibrous adhesions were readily
apparent between adjacent organs or between otherwise
free tissues and the abdominal wall. Organ fibrosis was
quantitatively scored by comparing the Hyp:Pro ratios
within tissues, which is a standard measure of collagen
content relative to total organ protein. Hyp:Pro ratios in
the kidney, liver, lung and heart were substantially
increased after coadministration of TGF-b2a n dC T G F ,
whereas treatment with either cytokine alone did not
increase Hyp:Pro ratios relative to vehicle controls (Table
1), thus demonstrating a clear interaction between CTGF
and TGF-b in this model. By these measures, Hyp:Pro
changes after coadministration of TGF-b2a n dC T G F
were most dramatic in kidney and liver (increases of 65%
and 160%, respectively, over control,), with more moder-
ate but significant increases of 34% and 11% being seen
in heart and lung, respectively (P < 0.001 in kidney, liver
and heart, P < 0.01 in lung). Because the latter tissues lie
outside the peritoneal cavity, this significant increase in
their relative Hyp:Pro content indicates that the intraper-
itoneal coadministration of TGF-b2 and CTGF elicited a
systemic rather than purely local fibrotic response. The
coadministration of CTGF and TGF-b2 was also asso-
ciated with a 28% reduction in final body weight (mean ±
SE 7.62 ± 0.10 g) compared with healthy controls (10.59
± 0.24 g), which was significant (P < 0.001). In addition,
the severe intra-abdominal fibrosis in these animals
appeared to be associated with compromised bowel moti-
lity, as indicated by increased accumulation of fecal mate-
rial in their intestines (data not shown).
Figure 1 The FG-3019 binding epitope overlaps with the VWC domain of connective tissue growth factor (CTGF). (A) The region of the
FG-3019 binding epitope (CTGF amino acids 142 to 157, indicated in yellow) is superimposed on the structure of the collagen IIa VWC domain
[50]. By sequence homology, the general structural features of this domain are predicted to be conserved in CTGF and other CCN (connective
tissue growth factor) proteins [51]. The predicted FG-3019 binding site lies outside of a fibronectin-1-like module within the VWC domain of
CTGF. A physical interaction between the VWC domain of Xenopus CTGF and TGF-b family members TGF-b1 and bone morphogenetic protein
(BMP)-4 was reported [9]. The location of the VWC domain relative to the insulin-like growth factor binding protein (IGF-BP), thrombospondin-1
(TSP1) and C-terminal cysteine knot (CT) homology domains of CCN family members is also indicated. (B) Recombinant human CTGF, CYR61 and
NOV proteins (visualized by Coomassie blue in the upper panel) were analyzed by western blot using FG-3019, anti-CYR61 and anti-NOV
antibodies. FG-3019 specifically bound CTGF without crossreacting with CYR61 or NOV.
Figure 2 Gross anatomy in the transforming growth factor-b/
connective tissue growth factor (TGF-b/CTGF) synergy model.
Peritoneal cavities of (A) healthy control animals, (B) animals
coadministered CTGF and TGF-b2, and (C) animals coadministered
CTGF and TGF-b2 and treated with anti-CTGF antibody FG-3019.
Extensive fibrotic membranes surrounded most organs in the
abdominal cavity in vehicle-treated mice that received both TGF-b2
and CTGF. A substantial reduction in gross fibrotic pathology was
observed in mice that received TGF-b2 and CTGF plus FG-3019.
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simultaneous treatment with FG-3019 resulted in sub-
stantial visible suppression of the peritoneal membrane
and abdominal cavity fibrotic responses (Figure 2C).
Overt intra-abdominal adhesions were not noted in
these animals. This qualitative reduction in gross fibrotic
effect was accompanied by a 22% improvement in the
mean final (day 21) body weight in the FG-3019-treated
cohort (9.32 ± 0.32 g) compared with animals that
received TGF-b2 and CTGF without FG-3019 treatment
(P < 0.001), although the FG-3019 treated animals were
still 12% lighter than healthy controls (P < 0.001). FG-
3019 treatment also substantially reduced Hyp:Pro ratios
in all organs examined. Specifically, the increase in rela-
tive Hyp:Pro content (that is, the fibrotic response) eli-
cited by coadministration of TGF-b and CTGF was
reduced by 63% in lung (P < 0.05), 25% in kidney (P <
0.05), 30% in liver (P < 0.01) and 15% in heart after FG-
3019 treatment (Table 1).
The observation that frank fibrosis only occurred after
coadministration of both TGF-b and CTGF, as opposed
to either cytokine alone, and that it was attenuated by
FG-3019 antibody treatment, was also confirmed by an
independent histologic analysis (Comparative Bios-
ciences, Inc., Sunnyvale, CA, USA). Microscopic analysis
of stained liver sections revealed multifocal fibrosis of
the hepatic capsule in eight of eight animals that
received both cytokines (Figure 3A, Table 2). In addi-
tion, multiple foci of trace or mild parenchymal fibrosis,
primarily in periportal liver regions, were present in
three animals that received both cytokines. Thus, the
response to TGF-b/CTGF coadministration was primar-
ily one of capsular fibrosis with occasional parenchymal
involvement. By contrast, histologic evidence of capsular
or parenchymal liver fibrosis was entirely absent in all
animals that received either CTGF or TGF-b alone, and
focal evidence of trace capsular fibrosis without par-
enchymal fibrosis was seen in only two of eight animals
that received FG-3019 (Figure 3B). Thus, the incidence
of any degree of fibrosis after dual-cytokine treatment
was significantly reduced by CTGF-targeted FG-3019
treatment (Fisher’s exact test, P = 0.007) and analysis of
variance by ranks showed that the histologic liver fibro-
sis severity scores (0 = no fibrosis, 1 = minimal, 2 =
minimal to mild, 3 = mild and 4 = moderate fibrosis)
for animals that received both TGF-b2 and CTGF (med-
ian 1.5, range 1 to 4) were significantly higher than for
animals that received vehicle, TGF-b2o rC T G Fa l o n e
(all scores = 0; Dunn’st e s t ,P < 0.001) and that they
were significantly reduced by FG-3019 treatment (med-
ian 0, range 0 to 1, P < 0.01). Likewise, mild to moder-
ate renal capsular fibrosis was observed in three of eight
animals that received both cytokines without FG-3019
treatment (Figure 3C), whereas no evidence of fibrosis
was seen in any other animal from any other group,
including the FG-3019 treatment group (Figure 3D).
Fibrosis of the renal parenchyma was not seen in any
animal in this study, nor was inflammation noted in any
tissue.
Effect of CTGF inhibition in a UUO-induced kidney fibrosis
model
Previous studies have demonstrated a direct correlation
between CTGF levels and renal pathology in the UUO-
induced kidney fibrosis model [16,27]. In the current
study, ligated kidneys of vehicle-treated animals were
compared with non-ligated control kidneys of the same
animals to determine the fibrotic effect of UUO using
the standard tissue Hyp:Pro ratio to assess the fibrotic
response. In addition, to determine whether disruption
of CTGF signaling inhibits the UUO-induced fibrotic
response, ligated kidneys of animals treated for 2 weeks
with either vehicle or FG-3019 were compared.
In vehicle-treated control animals, UUO induced a
clear fibrotic effect, as indicated by a fourfold increase
in the mean Hyp:Pro ratio in ligated kidneys compared
with non-ligated control kidneys (0.175 ± 0.011 vs.
0.045 ± 0.0005; P < 0.001). The kidneys of animals trea-
ted with 10 and 30 mg/kg FG-3019 were significantly
protected from UUO-induced fibrosis, as indicated by
Table 1 Hydroxyproline:proline ratio by treatment group and organ in the TGF-b/CTGF synergy model
Organ Control Treatments
- TGF-b2 - TGF-b2 TGF-b2
- - CTGF CTGF CTGF
- - - - FG-3019
Kidney 0.057 ± 0.001 0.061 ± 0.002 0.059 ± 0.001 0.094 ± 0.0051 0.085 ± 0.003
1,3
Liver 0.015 ± 0.001 0.017 ± 0.001 0.016 ± 0.002 0.039 ± 0.003
1 0.032 ± 0.002
1,4
Lung 0.079 ± 0.002 0.078 ± 0.002 0.083 ± 0.001 0.088 ± 0.001
2 0.083 ± 0.002
,3
Heart 0.041 ± 0.001 0.044 ± 0.002 0.046 ± 0.002 0.055 ± 0.002
1 0.053 ± 0.003
1
Data shown represent mean ± SEM, n = 6 to 10.
1P < 0.001,
2P < 0.01 compared with healthy control group, one way analysis of variance, Fisher’s least significant difference.
3P < 0.05,
4P < 0.01 compared with transforming growth factor (TGF)-b2 and connective tissue growth factor (CTGF) coadministration group.
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Hyp:Pro ratios compared with untreated UUO control
mice (P < 0.05) (Figure 4), respectively. Histologic analy-
sis using trichrome staining revealed interstitial fibrosis,
fibroblast proliferation and increased collagen accumula-
tion in all obstructed kidneys regardless of treatment,
with a slight but subjective decrease in the amount of
fibrosis seen in the 10 mg/kg FG-3019 treatment group
(not shown). Increased trichrome staining was asso-
ciated with the fibroblast proliferation, and was noted in
the interstitium of the cortex, the surrounding glomeruli
and the medullary regions of all obstructed kidneys.
Marked hydronephrosis, characterized by tubular
Figure 3 Hepatic and renal fibrosis in mice receiving transforming growth factor (TGF)-b and connective tissue growth factor (CTGF) is
ameliorated by FG-3019 treatment. (A, B) Liver and (C, D) kidney of 21-day-old animals coadministered TGF-b2 and CTGF; animals were
treated with either (A, C) vehicle or (B, D) FG-3019. All agents were administered daily for 20 days beginning one day after birth. Arrows
indicate regions of robust capsular fibrosis inhibited by FG-3019 treatment. Representative images are shown (all haematoxylin and eosin,
original magnification × 200).
Table 2 Incidence of histologic liver fibrosis by severity
score
Treatment Degree of liver fibrosis (score)
None
(0)
Minimal
(1)
Minimal to
mild (2)
Mild
(3)
Moderate
(4)
Vehicle 9 0 0 0 0
TGF-b28 0 0 0 0
CTGF 6 0 0 0 0
TGF-b2 + CTGF 0 4 2 1 1
TGF-b2 + CTGF
+ FG-3019
62 0 0 0
Values indicate the number of mice with each categorical liver fibrosis score.
Wang et al. Fibrogenesis & Tissue Repair 2011, 4:4
http://www.fibrogenesis.com/content/4/1/4
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throughout the cortex in all obstructed kidneys regard-
less of treatment. In addition, multifocal lymphocytic
infiltrates were commonly observed in the interstitium
of obstructed kidneys, particularly in perivascular
regions; however, this was also unaffected by treatment.
Effect of FG-3019 in a bleomycin-induced pulmonary
fibrosis model
To confirm that CTGF actively contributes to the
pathogenesis of pulmonary fibrosis, and that CTGF inhi-
bition may alleviate the pulmonary fibrotic response, the
effect of FG-3019 treatment was examined in a bleomy-
cin-induced lung fibrosis model [24,28]. Bleomycin-trea-
ted animals were compared with healthy controls to
determine the fibrotic effect of pulmonary bleomycin
instillation. Bleomycin-treated animals treated for 2
weeks with either vehicle or FG-3019 were further com-
pared, to investigate the importance of CTGF signaling
in pulmonary fibrogenesis. Fibrosis in this model was
scored by the standard measure of total lung Hyp,
which takes into account the variable Pro content in
lung, which is often unrelated to changes in total lung
collagen content.
In control mice, bleomycin treatment increased mean
± SEM Hyp content to 452 ± 18 μgp e rl u n g( n =6 )
compared with non-fibrotic saline-treated controls (285
±8μgp e rl u n g ;n = 10); a significant 59% increase of
167 μgp e rl u n g( P < 0.001). Compared with vehicle-
treated bleomycin controls,F G - 3 0 1 9a n t i - C T G Fa n t i -
body treatment resulted in a consistent reduction in
mean induced lung Hyp content; a 38% reduction in
induced fibrosis in the 10 mg/kg FG-3019 treatment
group exhibited a trend towards a treatment effect (P =
0.056) (Figure 5).
FG-3019 Plasma Concentration
Circulating FG-3019 antibody levels were measured by
ELISA to confirm FG-3019 exposure after intraperito-
neal injection in the studies described above. In the
bleomycin and UUO studies, mean ± SD FG-3019
plasma concentrations measured 48 hours after the final 0 10 30
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Figure 4 FG-3019 inhibits renal collagen deposition after
unilateral ureteral obstruction (UUO). Hydroxyproline:proline
(Hyp:Pro) ratios in renal tissues from UUO mice are expressed as the
mean change above the mean Hyp:Pro ratio of unligated control
kidneys (0.0446 ± 0.0005, n = 35). Mean renal Hyp:Pro ratio increases
for the 10 and 30 mg/kg FG-3019 treatment groups (gray bars)
were 20% and 15% lower than for the UUO kidneys of vehicle-
treated controls (white bar), respectively. *P < 0.05 compared with
UUO + vehicle (analysis of variance, Fisher’s least significant
difference).
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Figure 5 FG-3019 inhibits collagen deposition in lungs of
bleomycin-treated mice. Pulmonary hydroxyproline (Hyp) content
(μg/lung) of bleomycin-treated mice is expressed as the mean
change from Hyp content of healthy control lungs (285 ± 8 μg/
lung, mean ± SEM, n = 10). Mean Hyp content (μg/lung) increases
for the 3, 10 and 30 mg/kg FG-3019 treatment groups (gray bars)
were 27, 38 and 13% lower than for the bleomycin mice treated
with vehicle (white bar), respectively. *P = 0.056 vs. bleomycin +
vehicle (ANOVA, Fisher’s LSD).
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71.8 μg/mL, respectively. Consistent with the lower daily
and cumulative dose delivered in the neonatal TGF-b/
CTGF synergy study, the FG-3019 plasma concentration
24 hours after the final 1.84 mg/kg dose was 21.8 ± 11.5
μg/mL.
Discussion
Fibrosis, the excessive and persistent formation of scar
tissue, is responsible for the morbidity and mortality
associated with organ failure in a variety of chronic dis-
eases affecting the lung, kidneys, eyes, heart, liver and
skin. CTGF is strongly overexpressed in fibrotic tissue
and is directly linked to the chronic fibrotic effects of
TGF-b, VEGF, insulin-like growth factor, angiotensin II
and other factors. CTGF acts as a cofactor with TGF-b
to induce fibroblasts to become myofibroblasts that
deposit collagen, ultimately resulting in organ scarring
and dysfunction, and in the most severe forms, organ
failure and death. Indeed, CTGF levels in tissue, blood
or vitreal fluid have been shown to correlate with the
degree and severity of fibrosis in many diseases [29].
Examples include diabetic nephropathy, glomerulo-
sclerosis and IgA nephropathy (kidney), diabetic retino-
pathy and advanced macular degeneration (vitreal fluid),
cirrhosis, biliary atresia and nonalcoholic steatohepatitis
(serum, liver), congestive heart failure (myocardium),
and various forms of pulmonary and skin fibrosis
(serum, tissue) [5,29-32].
In the studies described here, the anti-CTGF antibody
FG-3019 consistently diminished fibrotic responses in a
novel model of CTGF and TGF-b synergy, and in pre-
viously described acute inflammatory models of lung and
kidney fibrosis. Thus, the anti-fibrotic activity of FG-3019
in each of these models supports a key role for CTGF in
mediating fibrogenesis. Indeed, FG-3019 alleviated the
fibrosis associated with acute bleomycin and UUO injury
even though the relatively severe nature of these acute
injury models may limit the observable treatment benefit.
It was not possible to determine from these models the
specific nature of the anti-fibrotic effects of FG-3019, and
additional studies will be needed to determine whether
the FG-3019 action is exerted directly through effects on
initiation, progression or resolution of fibrosis, or indir-
ectly via effects on initial injury and/or early inflamma-
tory response to injury [33]. Nevertheless, the UUO and
bleomycin models were chosen because they have been
extensively investigated, and because TGF-b and CTGF
have each been implicated in their development and pro-
gression [16,22-24,28]. Thus, in the lung and kidney
fibrosis models, endogenous TGF-b and CTGF were
induced [28], and in the CTGF and TGF-b synergy
model, recombinant exogenous TGF-b and CTGF were
coadministered directly, with the latter approach
resulting in profound encapsulating peritoneal sclerosis
and systemic multiorgan fibrosis. Thus, each model pro-
vides a useful scenario for investigating CTGF/TGF-b
cooperativity and the potential clinical utility of antifibro-
tic agents.
Previous findings indicated that coadministration of
CTGF and TGF-b is required for the establishment of a
persistent fibrotic effect in skin after subcutaneous
administration [21,34-36]. In the current cooperative
interaction model, intraperitoneal coadministration of
TGF-b2 and CTGF resulted in the development of pro-
found abdominal fibrosis and disseminated fibrosis in
extraperitoneal organs, thus indicating induction of a
systemic fibrotic response. Notably, induction of fibrosis
in this model required concomitant exposure to both
TGF-b and CTGF in a manner indicating functional
synergy between these two cytokines in the fibrogenic
response. These results indicate that CTGF is both
necessary and sufficient to initiate fibrosis in the pre-
sence of increased TGF-b s i g n a l i n g ,a n dt h a tT G F - b is
both necessary and sufficient to elicit fibrosis in the pre-
sence of increased CTGF. Because TGF-b is a potent
inducer of endogenous CTGF, it is important to con-
sider why the addition of further exogenous CTGF is
required for TGF-b to elicit an overt fibrotic response.
One possible explanation is that in the presence of
pathologic fibrosis, TGF-b is indeed required, but fails
to elicit enough endogenous CTGF on its own. This
implies that independent pathways of CTGF regulation
are also necessary. Moreover, it suggests that a CTGF
threshold must be met to initiate or maintain fibrogen-
esis, and if so, then even partial inhibition of its activity
to levels below a crucial threshold should provide anti-
fibrotic benefit. Indeed, in the cooperative interaction
model, FG-3019 anti-CTGF treatment reduced the over-
all level of fibrosis observed after CTGF and TGF-b
coadministration in liver, kidney and lung. The magni-
tude of Hyp:Pro changes is influenced by pre-existing
collagen content, the presence of less affected sample
areas, and potential accumulation of non-collagenous
proteins during fibrosis, whereas the histologic fibrosis
scores measure the overall microscopic appearance of a
tissue, including tissue areas that may be differentially
affected, such as capsular or parenchymal regions. Thus,
both measures support the qualitative conclusion that
CTGF and TGF-b cooperate to promote tissue fibrosis,
and that CTGF inhibition can suppress fibrogenesis.
Although the TGF-b/CTGF cooperative interaction
model has properties suggestive of broad relevance to
fibrotic disease, it may be specifically relevant to the for-
mation of abdominal adhesions after surgery and to
peritoneal fibrosis associated with dialysis procedures.
Fibrosis in the TGF-b/CTGF cooperative interaction
model was associated with profound peritoneal
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presentation in patients diagnosed with postoperative
peritoneal adhesions [37]. Moreover, CTGF mRNA is
significantly increased in postoperative adhesions after
peritoneal wounding in animal models [38] and in
patients undergoing peritoneal dialysis [39]. Thus, it is
likely that CTGF and TGF-b contribute to the forma-
tion of intra-abdominal adhesions in a cooperative and
potentially targetable manner.
Together, these data provide both gain- and loss-of-
function evidence that CTGF plays a crucial role in fibro-
t i ct i s s u ei n j u r y ,b e c a u s ee x o g e n o u sC T G Fw a sr e q u i r e d
to initiate a fibrotic response in the presence of increased
TGF-b levels, and because treatment with a CTGF-
blocking antibody attenuated the fibrotic response in
three independent models of pathologic fibrosis. More-
over, with regard to clinical utility, these data support the
conclusion that the anti-CTGF monoclonal antibody,
FG-3019, may be useful in controlling the progression of
renal, pulmonary and hepatic fibrosis in patients with dis-
eases such as diabetic nephropathy, systemi sclerosis or
idiopathic pulmonary fibrosis. These results were
obtained in studies of relatively limited treatment dura-
tion (14-20 days), as required by use of a human antibody
in rodents, so that the added benefit of longer duration
treatment regimens could not be assessed. In these stu-
dies, the optimum dose and regimen for FG-3019 admin-
istration was not fully established, and may differ by
disease. However, the antifibrotic effects of FG-3019 have
been reproduced in other studies, including comparisons
where non-immune IgG groups were used [40].
CTGF exhibits a broad spectrum of biological activ-
ities, including effects on bone and cartilage develop-
ment [41], cell adhesion and chemotaxis [42], and
angiogenesis [43], none of which were addressed in
these experiments. Moreover, fibrotic tissue remodeling
also influences other clinically relevant processes,
including cancer progression and organ-graft rejection.
In addition to its antifibrotic effects, the FG-3019 anti-
CTGF antibody used here has also been shown to
attenuate tumor growth, metastasis and angiogenesis in
mouse models of pancreatic cancer and to attenuate the
anchorage-independent growth of CTGF-overexpressing
pancreatic cancer cells [44-46]. Thus, taken together,
these studies indicate that CTGF is a clinically relevant
target in fibrosis and other disease states.
Methods
Animal selection and handling
Mice (Charles River Laboratories, Inc., Wilmington, MA,
USA) were handled according to standards provided in
the National Institutes of Health Guide and the Animal
Welfare Act and to protocols approved by the Institu-
tional Animal Care and Use Committee.
UUO kidney fibrosis study
In total, 40 male Swiss Webster mice (32-35 g) were
assigned to one of four groups (10 mice/group). On the
first day of dosing, mice received an intraperitoneal dose
of vehicle or FG-3019 (10 or 30 mg/kg), and 4 hours
later, mice were anesthetized with isoflurane and UUO
was performed on the left kidney [22]. The right (unop-
erated) kidney served as control. Thereafter, mice
received vehicle or FG-3019e v e r yo t h e rd a yt og i v ea
total of seven doses. Fourteen days after UUO, the sur-
viving mice were anesthetized with isoflurane, blood was
collected via the abdominal vein for plasma FG-3019
concentration by ELISA, and both the left and right kid-
neys were harvested. Mice that survived to the sched-
uled termination date were examined for successful
ureteral ligation. Five mice with unsuccessful ligations
(one from the UUO and vehicle group and four from
the UUO and 10 mg/kg FG-3019 group) were excluded
from analysis. Half of each kidney was processed for his-
topathologic analysis. The remaining half of each kidney
was processed for determination of Hyp and Pro levels.
Bleomycin-induced lung fibrosis study
In total, 40 male C57BL/6 mice (23-26 g) were assigned
to one of four bleomycin-treated fibrosis groups (10
mice/group) and treated with FG-3019 (3, 10 or 30 mg/
kg) or vehicle (control group). On the first dosing day,
mice received an intraperitoneal dose of either vehicle
or FG-3019, and 2 hours later received an intratracheal
instillation of bleomycin (Bristol-Myers Squibb, Prince-
ton, NJ, USA) at a dose of 0.08 U/50 μL/mouse under
isoflurane anesthesia [24,47]. An additional non-fibrosis
control group of 10 mice received an intratracheal instil-
lation of saline, and was treated with vehicle. Thereafter,
mice received vehicle or FG-3019 every other day to
give a total of seven doses. During the dosing period,
mice were observed daily, and weights were measured
approximately three times per week. Animal weights in
all bleomycin treatment groups were somewhat reduced
versus saline non-bleomycin control, but final weights
did not differ significantly between treatment groups.
Similarly, bleomycin-associated mortality was similar
between groups exposed to this agent. Fourteen days
after the bleomycin instillation, the surviving mice were
anesthetized with isoflurane. Blood was collected from
the abdominal vein and placed in lithium-heparin tubes
and spun at 4°C, then the plasma was frozen at -70°C
for subsequent determination of FG-3019 concentration.
All dissected lung lobes were quickly freed of non-par-
enchymal tissue, perfused with ice-cold saline, and
hydrolyzed in 6 mol/l HCl at 105°C for 22 hours for
subsequent whole-lung Hyp determination by high-
performance liquid chromatography (HPLC) amino acid
analysis. The standard measure of total lung Hyp in this
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tion of bleomycin injury associated with intratracheal
instillation. Owing to the non-uniform nature of local
bleomycin injury, histology samples were not collected.
TGF-b/CTGF synergy study
T e np r e g n a n tf e m a l eB a l b / cm i c ew e r eu s e d ,w i t ht w o
dams assigned to each of five experimental groups to pro-
vide seven to 10 neonates per group. In each group, neo-
nates were treated with up to two cytokines and with
vehicle or FG-3019, as follows: no cytokine vehicle treat-
ment control (healthy control; n = 10 neonates); TGF-b2
and vehicle (n = 7 neonates); CTGF and vehicle (n =7n e o -
nates); TGF-b2 and CTGF and vehicle (n = 10 neonates);
and TGF-b2a n dC T G Fa n dF G - 3 0 1 9( n =8n e o n a t e s ) .
Mice aged 1 day old received their first intraperitoneal
dose of FG-3019 (1.84 mg/kg) or vehicle (both in a
volume of 0.05 mL), followed 1 hour later by intraperi-
toneal administration of recombinant human TGF-b2
(300 μg/kg) and/or CTGF (300 μg/kg) in a volume of
0.05 mL. This dosing regimen continued once daily for
20 consecutive days. Two mice died: one in the CTGF
group (on day 10) and one in the group coadministered
TGF-b2 and CTGF (on day 21, before scheduled termi-
nation). One day after the final FG-3019 dose, surviving
mice were weighed and killed after blood collection for
determination of plasma FG-3019 concentration. Organs
were harvested for histopathologic analysis (kidney and
liver) and determination of total Hyp and Pro (kidney,
lung, liver and heart).
Hyp and Pro determination
Hydroxyproline and proline were determined by the
method of Palmerini et al. [48], except that L-azetidine
2-carboxylic acid (Sigma-Aldrich, St Louis, MO, USA)
was substituted for 3,4-dehydroproline as an internal
standard. Tissues were hydrolyzed in 6M HCl for 22
hours at 105°C. Samples underwent pre-column deriviti-
zation with o-phthalaldehyde and then 4-chloro-7-nitro-
benzofuran (Sigma-Aldrich) to form fluorescent adducts
of proline and hydroxyproline. The fluorescent adducts
were separated and determined by reverse-phase HPLC
followed by fluorometric detection.
Histologic analysis
Tissue sections were independently examined in an
unblinded manner by a licensed pathologist (Comparative
Biosciences, Inc.). In the dual-cytokine synergy study, tis-
sue sections were stained with hematoxylin and eosin and
with trichrome, and a subjective but relative fibrosis sever-
ity score from 0 to 4 was assigned for each examined
organ as given in Results, with small focal areas of trace
fibrosis constituting ‘minimal’ fibrosis, and larger
multifocal (that is,, non-diffuse) areas of fibroblasts and
extracellular matrix accumulation constituting ‘moderate’
fibrosis.
Test articles
FG-3019 was cloned, expressed and purified from a
recombinant CHO cell line derived for this purpose. For
bleomycin and UUO studies, FG-3019 was prepared in a
vehicle solution consisting of 25 mmol/l L-histidine and
137 mmol/l sodium chloride, pH 6.0. For the TGF-b
and CTGF synergy study, FG-3019 was prepared in
phosphate-buffered saline (PBS; Cellgro™, Mediatech,
Herndon, VA, USA). E. coli-derived TGF-b2 and baculo-
virus-derived recombinant human CTGF [49] were also
prepared in PBS vehicle.
Immunologic methods
Immunoblotting was carried out according to standard
western blotting methods. FG-3019 or polyclonal anti-
sera directed against either CYR61 or NOV were each
used to determine the relative affinity of antibody pre-
parations towards baculovirus-derived recombinant
human CTGF, CYR61 and NOV. Rabbit polyclonal anti-
NOV and anti-CYR61 antisera were generous gifts from
Drs Maryvonne Laurent (Hôpital St. Antoine; Paris,
France) and Ruth Lupu (UC Berkeley; Berkeley, CA,
USA), respectively. For determinations of relative FG-
3019 exposure, plasma FG-3019 antibody concentrations
were determined by a sandwich ELISA using an exon-3
(VWC homology domain) CTGF peptide for capture of
FG-3019 followed by detection with goat anti-human
IgG linked to alkaline phosphatase.
Statistical analysis
Statistical analyses were performed using the Sigma Stat
program (SPSS Science, Chicago, IL, USA). Continuous
data were analyzed by one-way analysis of variance with
the Fisher’s least significant difference test comparing all
groups. Ordinal histologic fibrosis scores were analyzed
by the non-parametric Kruskal-Wallis statistic with
Dunn’s multiple comparison post-hoc tests. The Fisher’s
exact test was used to analyze 2 × 2 contingency data
for the presence or absence of histologic fibrosis. In the
UUO study, Hyp:Pro ratios from uninjured contralateral
control kidneys from all groups were pooled with the
healthy control group. P < 0.05 was considered statisti-
cally significant, and unless otherwise indicated, within-
group distributions are expressed as mean ± SEM.
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